strategies for patients with skin eruptions caused by H pylori eradication therapy. As a result, it would be possible to reattempt or resume H pylori eradication therapy when skin eruptions develop because drug eruptions could be ruled out.
1
cell-mediated immune reaction.
Finally, H pylori components in EVs can induce skin manifestations during antibiotic treatment. A test to identify H pylori sensitivity would be highly useful to distinguish such sensitivity from antibiotic hypersensitivity. Transcutaneous CO-oximetry differentiates asthma exacerbation and convalescence in children
To the Editor:
There is a paucity of inflammatory biomarkers for asthma exacerbation, and current options require patient effort or discomfort and have not significantly affected management. 1 Biologic production of carbon monoxide (CO) as a result of hemeoxygenase-1 upregulation in response to oxidative stress 2 has been associated consistently with asthma activity. 3 Increased levels of exhaled breath condensate CO and arterial carboxyhemoglobin are associated with loss of control and decrease with appropriate steroid therapy. [4] [5] [6] In this context we tested whether pulse CO-oximetry (carbon monoxide percent saturation of hemoglobin [SpCO] ) is associated with asthma exacerbation in a prospective observational cohort. 7 Children aged 6 to 17 years with a history of physician-diagnosed asthma were enrolled during an emergency department visit for acute asthma exacerbation and returned 6 weeks later for a follow-up research visit (ie, the convalescent visit) when they had returned to symptomatic baseline (see Fig E1 in this article's Online Repository at www.jacionline.org). A comparison cohort of similar subjects with asthma but not identified by exacerbation was derived from baseline assessment of the School Inner City Asthma Intervention Study (SICAS-2; ClinicalTrials.gov:NCT02291302). The study was approved by the Boston Children's Hospital Institutional Review Board.
SpCO values were measured with the Rad-57 device (Masimo, Irvine, Calif) at the exacerbation and convalescent visits. Paired t tests evaluated the mean difference between exacerbation and convalescence values for SpCO measurements in the primary analysis and by using t tests for comparison with ambulatory visit measures (SICAS-2). Complete study methods are provided in the Methods section in this article's Online Repository at www.jacionline.org.
Fifty-nine subjects were included in the paired analysis. Subjects had a mean age of 11 years and were predominately black (37%) and Hispanic (39%). Fifteen percent of subjects were white. Eight (14%) subjects had frequent environmental tobacco smoke exposure (see Table E1 in this article's Online Repository at www.jacionline.org). Compared with the primary cohort, the SICAS-2 comparison group was younger (11.0 vs 7.7 years old), was less aeroallergen sensitized (91% vs 60% with any aeroallergen sensitization), and had lower FEV 1 (109.6% vs 98.6% of predicted value) values but not level of obstruction based on FEV 1 /forced vital capacity ratio.
There was a significant difference between exacerbation and convalescent mean SpCO values (6.02% 6 2.8% vs 3.42% 6 2.0%, P < .0001). Moreover, evaluation of each subject's mean SpCO regression (Fig 1) Table E2 in this article's Online Repository at www.jacionline.org). There were significant differences in SpCO values between the mean exacerbation and convalescent values, and, interestingly, between the convalescent values of children with prior exacerbation and the ambulatory SICAS-2 population (SICAS-2 SpCO mean, 1.44; SD, 1.96; P < .001 for bivariate comparison with exacerbation and convalescent values; Fig 2) .
Our study demonstrates that SpCO measurement differentiates reliably between asthma exacerbation and convalescent state after recovery in children who present to the emergency department and further discriminates the convalescent state from well-controlled asthma without recent exacerbation. The prospective methodology of this study design with repeated measures suggests that transcutaneous carboxyhemoglobin is a potentially important biomarker of asthma exacerbations and might fill a void in personalized asthma monitoring.
The biologic plausibility of carboxyhemoglobin as a biomarker for asthma control has been well established. 2, 3, 6 Transcutaneous CO-oximetry values have been associated with increased Asthma Control Test scores in a cross-sectional clinic cohort. 8 However, Naples et al 9 found that SpCO values were not diagnostic for asthma in adults. Our results and those of Naples et al would suggest that the clinical utility of SpCO is as a measure of asthma activity during exacerbations but not as a diagnostic test for asthma. Potential clinical use will be limited to monitoring patients at risk for exacerbation but not for asthma diagnosis.
It is important to recognize that our study design identified subjects at the extremes of asthma control: emergency exacerbation and convalescence after intensive treatment. Although we identified a clear distinction in SpCO values between these states, the design does not lend itself to determining whether the SpCO value is a predictive marker in advance of exacerbations or whether it can be generalized to ambulatory patients with asthma. Additionally, fundamental differences between the SICAS-2 comparison group and the primary cohort of children presenting with exacerbation might also contribute to differences in SpCO values.
Transcutaneous CO-oximetry is a reliable biomarker of asthma exacerbation in children with asthma. The noninvasive, effort-independent, simple-to-perform measurement makes its application to clinical practice appealing. However, further investigation to determine its clinical utility in predicting loss of asthma control above currently available measures is needed.
We thank the study staff, participants, and families who contributed to this research. We also thank Alicia Casey, MD, for her intellectual contribution to the study. Efficacy and long-term protection of subcutaneous allergen immunotherapy (AIT) to Betulacea pollens have been well demonstrated. To achieve long-term protection, treatment has to be classically maintained for 3 or more years. [1] [2] [3] We have approached the issues of AIT differently by providing a safe and short (2 months) immunotherapy protocol using long contiguous overlapping peptides (COPs, 5 subcutaneous injections).
4-6 COP treatment significantly improved allergic rhinitis combined symptom and medication score (RSMS) in a recent double-blind, multinational, placebo-controlled phase IIb trial (acronym AN004T) after a first seasonal exposure to birch pollen (50 mg dose). 5 Treatment with Bet v 1 COPs induced Bet v 1-specific IgG 4 levels, 5 which remained elevated over the course of 4 seasons in a phase I/IIa clinical trial. 6 One of the major interests of AIT is its capacity not only to induce tolerance to the allergen but also to act as a disease-modifying therapy. It was thus of the utmost importance to demonstrate the long-term persistence of the efficacy of this innovative AIT approach.
We therefore report here the clinical efficacy of the AN004T immunotherapy trial 5 during a second seasonal exposure to birch pollen (study AN005T). One hundred ninety-six of 240 randomized subjects (81.7%) returned for a second birch pollen season evaluation without having received any additional Bet v 1 COP treatment or other AIT (see Fig E1 in (Fig 1, A) . Similar results were obtained in the modified intent-to-treat set (n 5 189, 50 mg group [adjusted mean difference from placebo of 20.162 with 95% CL, 20.325 to 20.001; P 5 .05] and 100 mg group [adjusted mean difference from placebo of 20.120 with 95% CL, 20.288 to 0.049; P 5.16]).
Among secondary end points, subjective quality of life was assessed by Mini Rhinoconjunctivitis quality-of-life questionnaire and both treatment groups had lower scores when compared with placebo and improvement reached statistical significance (Mini Rhinoconjunctivitis quality-of-life questionnaire improvement, 21% and 20%; adjusted mean difference from placebo of 20.394 and 20.379; P 5 .03 and P 5 .05, respectively) (Fig 1, B) . Nighttime nasal symptom score, an assessment widely used to evaluate the severity of allergic rhinitis, was significantly improved (mean improvement, 31% and 39%; adjusted mean difference from placebo of 20.212 and 20.268; P 5.01 and P 5.003 for 50 mg and 100 mg groups, respectively) (Fig 1, C) .
Overall, 54.7%, 50.9%, and 38.8% of subjects in Bet v 1 COP 50 mg, Bet v 1 COP 100 mg, and placebo groups, respectively, rated themselves improved from the previous season.
For the sake of comparison between AN004T and AN005T trials, Fig 2 summarizes results obtained in the same per-protocol set of both trials. Data showed strong consistency from first season to second season with an expected decrease in efficacy that nevertheless always remained 20% or more from placebo when significant (Fig 2, A-C) .
Bet v 1-specific IgG 4 increased by 10-to 20-fold after Bet v 1 COP treatment and remained elevated during the first birch pollen season (AN004T). 5 Before the second season (V15), Bet v 1-specific IgG 4 had decreased but remained elevated (2-3 times) compared with placebo and the pretreatment level (see Fig E3, A and B, in this article's Online Repository at www.jacionline.org). A small further increase in Bet v 1-specific IgG 4 was observed during the second pollen season in all 3 treatment groups (V16-V17). Antibody responses to COPs are shown in Fig E4 in this article' s Online Repository at www.jacionline. org. Nearly all subjects had a positive skin prick test result to birch pollen extract at the end of the second season, regardless of the treatment group (93.9%, 96.8%, and 98.5% of subjects in the Bet v 1 COP 50 mg, Bet v 1 COP 100 mg, and placebo groups, respectively).
In conclusion, we present here the first successful phase IIb AIT trial based on COP reporting significant persistent clinical 
METHODS
This study population was nested in a previously described prospective observational cohort. E1 Children aged 6 to 17 years with a history of physician-diagnosed asthma and presenting to the emergency department with an acute exacerbation of asthma were invited to participate. Exclusion criteria included radiographic evidence of pneumonia, prematurity, immunodeficiency, and other nonasthmatic pulmonary or structural airways disease. All subject's guardians provided written informed consent, and subjects provided assent before participation. The study was approved by the Boston Children's Hospital Institutional Review Board.
Children were recruited at presentation to the emergency department at Boston Children's Hospital on a continuous basis through all seasons. Subjects were enrolled during acute asthma exacerbation and returned for a follow-up research visit 6 weeks later when they had returned to symptomatic baseline; see Fig E1 for the study schematic. Here the initial assessment is referred to as the ''exacerbation visit'' and the follow-up visit as the ''convalescent visit.''
Study procedures
At enrollment, sociodemographic factors, symptoms, environmental exposures, and medical history were ascertained by means of questionnaire. At exacerbation and convalescent visits, SpCO values were measured transcutaneously by using the Rad-57 device (Masimo), according to the manufacturer's standard procedure, in 3 sequential measurements. The Rad-57 probe was applied to the ring finger of the nondominant hand, provided there was no impediment to blood flow in that arm. The device was in place for a minimum of 30 seconds to stabilize on a reading, and a pulse index of greater than 1 was required for valid measurement. The probe was removed for 10 seconds between sequential tests. Each measurement was recorded as a whole integer representing the SpCO value. Spirometry (Morgan Scientific, Haverhill, Mass) was performed at the convalescent visit according to American Thoracic Society criteria.
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Measures
Mean SpCO values were calculated from 3 measurements at each visit and used in all analyses. Disposition from the emergency department was captured as follows: discharge to home or admission to an inpatient unit.
Statistical analysis
The primary analysis included only subjects with measured SpCO values at both the exacerbation and convalescent visits. Random-effects models were used to describe the variability of SpCO values between measurements performed at the same visit. Paired t tests were used to determine the mean difference between exacerbation and convalescence SpCO values. Sensitivity analysis was performed similarly to test whether significant associations were driven by subjects with more severe initial exacerbations by nature of requiring hospital admission versus discharge to home from the emergency department. Receiver operating characteristic curves were created to demonstrate associations of SpCO values with the dependent variable of exacerbation and convalescent visits. Spaghetti plots illustrate within-subject trends for mean SpCO values between the exacerbation and convalescent visits.
Next, we compared exacerbation and convalescent SpCO values from this cohort with those of an ambulatory pediatric asthma cohort. For this analysis, exacerbation and convalescent SpCO values were compared with values collected from the SICAS-2 cohort (ClinicalTrials.gov Identifier: NCT02291302) to compare with those of asthmatic patients not identified by severe exacerbation. These subjects are school-aged children with a diagnosis of asthma and at least 1 asthma symptom in the past 12 months who are followed for 1 year in an environmental intervention study framework in their classrooms. E3 One hundred eight subjects from the SICAS-2 intervention trial had SpCO values obtained at the summer baseline visit at study enrollment.
Statistical computations were performed with STATA software, version 13.1 (StataCorp, College Station, Tex). All tests were 2-tailed, and P values of les than .05 were considered significant.
RESULTS
Reliability of the Rad-57 device
The precision of SpCO measurements was determined by using the estimated SD of the residual error from a random-effects model of the 3 within-subject measured values. The exacerbation visit SD was 1.6% (95% CI, 1.4% to 1.8%), and the convalescent visit SD was 2.0% (95% CI, 1.9% to 2.2%). These values are consistent with the manufacturer's report of variation between measurements.
E4
Sensitivity analysis
Stratified analysis by disposition (ie, admitted vs discharged from the emergency department) demonstrated a significant increase in SpCO values at the time of exacerbation compared with convalescence in both groups. Subjects admitted to the hospital had a mean difference between exacerbation and convalescence of 3.4% (95% CI, 2.6% to 4.1%; P < .001), and subjects discharged home had a mean difference of 1.7% (95% CI, 0.5% to 2.8%; P 5 .005). Although the magnitude of that difference was greater in the patients admitted to the hospital compared with those discharged home, these results support the main study findings, regardless of the severity of the initial exacerbation. 
